Sichuan Biokin Pharmaceutical Co.,Ltd. (SHA:688506)

SHA:688506 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	2,967	5,177	3,220	403.96	1,005	154.22
Short-Term Investments	-	2,504	2,533	-	-	-
Trading Asset Securities	2,058	2,159	-	-	-	-
Cash & Short-Term Investments	5,025	9,840	5,753	403.96	1,005	154.22
Cash Growth	37.00%	71.04%	1324.16%	-59.79%	551.49%	-36.99%
Accounts Receivable	83.37	100.35	138.71	137.85	267.92	134.95
Other Receivables	17.42	19.4	34.33	3.9	5.14	2.95
Receivables	100.79	119.75	173.05	141.75	273.06	137.9
Inventory	144.68	146.31	162.19	140.91	101.33	82.33
Other Current Assets	4,735	384.42	218.87	89.2	47.22	49.36
Total Current Assets	10,006	10,491	6,307	775.82	1,426	423.81
Property, Plant & Equipment	876.64	816.31	573.09	534.79	420.26	404.98
Other Intangible Assets	29.99	30.3	26.68	28	29.53	31.16
Long-Term Deferred Tax Assets	53.56	38.21	179.2	76.18	83.23	65.8
Long-Term Deferred Charges	29.08	30.46	18.4	1.82	1.79	1.16
Other Long-Term Assets	50.58	41.79	32.79	8.5	30.28	24.54
Total Assets	11,046	11,448	7,137	1,425	1,991	951.46

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	603.15	206.83	219.25	160.17	128.85	45.96
Accrued Expenses	63.01	621.31	437.25	257.88	244.81	139.81
Short-Term Debt	-	100.08	595.5	275.12	155.13	161.23
Current Portion of Long-Term Debt	1,067	841.49	235.28	174.37	30.47	0.02
Current Portion of Leases	-	23.9	12.46	46.13	68.82	24.23
Current Income Taxes Payable	7.59	-	14.13	0.01	4.96	1.54
Current Unearned Revenue	7.25	7.31	356.13	8.67	17.42	10.78
Other Current Liabilities	252.42	137.74	109.94	131.48	86.74	87.75
Total Current Liabilities	2,000	1,939	1,980	1,054	737.2	471.32
Long-Term Debt	3,110	2,616	1,189	183.92	239.96	50
Long-Term Leases	141.26	132.8	28.13	8.65	52.95	51.42
Long-Term Unearned Revenue	123.91	125.82	42.27	15.63	13.29	31.04
Long-Term Deferred Tax Liabilities	18.02	4.32	1.94	-	0.08	-
Other Long-Term Liabilities	8.22	7.58	9.73	11.19	14.05	15.81
Total Liabilities	5,402	4,825	3,251	1,273	1,058	619.61

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	412.87	412.87	401	401	401	360.9
Additional Paid-In Capital	4,670	4,659	885.84	858.69	858.55	14.17
Retained Earnings	770.38	1,545	2,599	-1,109	-328.45	-45.98
Comprehensive Income & Other	-10.01	5.5	0.53	1.13	2.79	2.76
Total Common Equity	5,644	6,623	3,886	151.87	933.89	331.85
Shareholders' Equity	5,644	6,623	3,886	151.87	933.89	331.85
Total Liabilities & Equity	11,046	11,448	7,137	1,425	1,991	951.46

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	4,318	3,714	2,061	688.19	547.33	286.91
Net Cash (Debt)	706.95	6,126	3,692	-284.23	457.41	-132.69
Net Cash Growth	-15.57%	65.91%	-	-	-	-
Net Cash Per Share	1.74	15.18	9.21	-0.71	1.26	-0.37
Filing Date Shares Outstanding	412.87	412.87	401	401	401	360.9
Total Common Shares Outstanding	412.87	412.87	401	401	401	360.9
Working Capital	8,006	8,552	4,327	-278.01	689.14	-47.51
Book Value Per Share	13.67	16.04	9.69	0.38	2.33	0.92
Tangible Book Value	5,614	6,592	3,859	123.88	904.36	300.69
Tangible Book Value Per Share	13.60	15.97	9.62	0.31	2.26	0.83
Buildings	-	323.1	325.3	304.56	302.23	300.82
Machinery	-	717.87	640.12	554.25	439.83	419.75
Construction In Progress	-	115.8	35.51	81.37	67.21	18.18

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 9, 2026

Data Sources Report a data error